Disparities in Endometrial Cancer Mortality: Will Increasing Use of Targeted Therapies Widen the Gap? Urothelial carcinoma (UC) is the most common malignancy of the urinary tract, with urothelial ...
Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Pre-specified thresholds for statistical significance were not met. Nivolumab plus ipilimumab did not improve overall survival (OS) when compared to chemotherapy in a phase 3 trial of patients with ...
For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...
Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...
Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...
Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results